Kai Ye

524 total citations
9 papers, 436 citations indexed

About

Kai Ye is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Kai Ye has authored 9 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cancer Research, 5 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Kai Ye's work include Cancer-related molecular mechanisms research (4 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (2 papers). Kai Ye is often cited by papers focused on Cancer-related molecular mechanisms research (4 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (2 papers). Kai Ye collaborates with scholars based in China, Singapore and United States. Kai Ye's co-authors include Peng Li, Chuncai Zhou, Hongwei Duan, Yin Fun Poon, Mary B. Chan‐Park, Shahrzad Rayatpisheh, Paula T. Hammond, Jianhua Xu, Ya‐Feng Sun and Junxing Chen and has published in prestigious journals such as Advanced Materials, Angewandte Chemie International Edition and Biochemical and Biophysical Research Communications.

In The Last Decade

Kai Ye

8 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kai Ye China 7 188 178 127 89 63 9 436
Kan Hu China 10 215 1.1× 151 0.8× 134 1.1× 83 0.9× 218 3.5× 16 611
Usama Abbasi Canada 10 122 0.6× 67 0.4× 49 0.4× 13 0.1× 52 0.8× 12 357
Satoshi Osada Japan 10 191 1.0× 205 1.2× 42 0.3× 18 0.2× 18 0.3× 34 389
Ajay Gupta India 10 261 1.4× 87 0.5× 20 0.2× 26 0.3× 82 1.3× 21 443
Zhuoquan Li China 10 247 1.3× 46 0.3× 29 0.2× 35 0.4× 247 3.9× 11 586
Chunlei Wu China 15 245 1.3× 114 0.6× 33 0.3× 16 0.2× 78 1.2× 29 461
Wenya Zhou China 13 228 1.2× 36 0.2× 27 0.2× 22 0.2× 146 2.3× 19 469
Lubomir Vezenkov France 11 217 1.2× 162 0.9× 34 0.3× 17 0.2× 16 0.3× 25 346
Xuexuan Wang Ireland 8 343 1.8× 244 1.4× 23 0.2× 8 0.1× 72 1.1× 9 692
Oksana V. Bondar Russia 11 149 0.8× 94 0.5× 15 0.1× 19 0.2× 74 1.2× 21 339

Countries citing papers authored by Kai Ye

Since Specialization
Citations

This map shows the geographic impact of Kai Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Ye more than expected).

Fields of papers citing papers by Kai Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Ye. The network helps show where Kai Ye may publish in the future.

Co-authorship network of co-authors of Kai Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Ye. A scholar is included among the top collaborators of Kai Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Ye. Kai Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Ye, Kai, Gang Shi, Jian Xu, et al.. (2025). Olaparib reverses prostate cancer resistance to Rapamycin by promoting macrophage polarization towards the M1 phenotype. Molecular and Cellular Biochemistry. 480(6). 3907–3921.
2.
Ye, Kai, et al.. (2022). PD-1 blockage combined with vaccine therapy can facilitate immune infiltration in tumor microenvironment of Lynch syndrome colon cancer. Frontiers in Genetics. 13. 877833–877833. 2 indexed citations
3.
Yang, Huiting, Kai Ye, Zhicheng Ye, et al.. (2022). A Light‐Driven Molecular Machine Controls K + Channel Transport and Induces Cancer Cell Apoptosis. Angewandte Chemie International Edition. 61(26). 59 indexed citations
4.
Zhou, Yu, et al.. (2021). MiR-328–3p inhibits lung adenocarcinoma-genesis by downregulation PYCR1. Biochemical and Biophysical Research Communications. 550. 99–106. 22 indexed citations
5.
Li, Caiping, et al.. (2020). LncRNA RAD51‐AS1/miR‐29b/c‐3p/NDRG2 crosstalk repressed proliferation, invasion and glycolysis of colorectal cancer. IUBMB Life. 73(1). 286–298. 33 indexed citations
6.
Wang, Jintian, et al.. (2019). Reduced miR-203 predicts metastasis and poor survival in esophageal carcinoma. Aging. 11(24). 12114–12130. 12 indexed citations
7.
Ye, Kai, et al.. (2017). Loss of BMI‐1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD‐2/MyD88‐mediated NF‐κB signaling. Journal of Cellular Biochemistry. 119(2). 1922–1930. 31 indexed citations
8.
Ye, Kai, et al.. (2016). TLR4 siRNA inhibits proliferation and invasion in colorectal cancer cells by downregulating ACAT1 expression. Life Sciences. 155. 133–139. 38 indexed citations
9.
Li, Peng, Chuncai Zhou, Shahrzad Rayatpisheh, et al.. (2012). Cationic Peptidopolysaccharides Show Excellent Broad‐Spectrum Antimicrobial Activities and High Selectivity. Advanced Materials. 24(30). 4130–4137. 239 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026